DCN and prostate neoplasm: However, in spite of highly individual changes in proteoglycans expression patterns in prostate tumours (versican/GAPDH ratio varies between 0.93 and 3.01; decorin/GAPDH ratio 0.33–2.26; lumican/GAPDH ratio 0.34–0.49; absence or presence of glypican-1, syndecan-1, aggrecan, or NG2), some tendencies were outlined from the RT-PCR data (Figure 3).